0.03Open0.03Pre Close0 Volume5 Open Interest2.50Strike Price0.00Turnover384.69%IV97.66%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier5DDays to Expiry0.03Extrinsic Value100Contract SizeAmericanOptions Type0.1209Delta0.3308Gamma42.67Leverage Ratio-0.0105Theta0.0000Rho5.16Eff Leverage0.0003Vega
Adaptimmune Therapeutics Stock Discussion
Adaptimmune Therapeutics plc, a company in T-cell therapies, and Galapagos NV, recognized for its innovative approaches to drug discovery and development, have announced a clinical collaboration agreement. This partnership focuses on the exclusive licensing option for Adaptimmune's TCR T-cell therapy candidate, uza-cel, specifical...
If approved, afami-cel will be the first engineered T-cell therapy for solid tumors and the first effective treatment option for synovial sarcoma in more than a decade.
(Type of Cancer) Synovial Sarcoma : There are more than 50 different types of soft tissue sarcomas which are categorise...
No comment yet